# HELP catalysts: Helus Pharma Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/help/catalysts

> Helus Pharma Inc. (HELP) has 2 upcoming catalysts. The next is the HLP004 trial start, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, half-year only, month only, quarter only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for HELP?

Helus Pharma Inc. (HELP) has 2 upcoming catalysts. The next is the HLP004 trial start, Q1 2027. Press release filed with the SEC (EX-99): "The Company expects to spend approximately $6,329 to initiate a Phase 2 monotherapy study by the end of Q1 2027.16 No amounts were spent toward the achievement of this milestone during the six months ended September 30, 2026." [Calendar and source filings](https://sec-api.dev/companies/help/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001833141-26-000100, https://www.sec.gov/Archives/edgar/data/1833141/000183314126000100/helus-mdaxq2x27.htm (retrieved 2026-11-13). Last confirmed 2026-11-13. Cite: https://sec-api.dev/companies/help/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Helus Pharma Inc. |
| Ticker | HELP (Nasdaq) |
| SEC CIK | 1833141 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/help |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| October 31, 2023 | [HLP003 interim data readout](https://sec-api.dev/pdufa/hlp003) | HELP | moderate to severe MDD | completed, met | "On October 31, 2023, the Company announced Phase 2a interim results for HLP003, demonstrating a rapid, robust and statistically significant reduction in symptoms of depression three weeks following a single 12 mg dose compared to placebo, in participants with moderate to severe MDD." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1833141/000183314126000058/cybin-mdaxq1x27.htm)) |
| October 31, 2023 | [CYB003 interim data readout](https://sec-api.dev/pdufa/cyb003) | HELP | moderate to severe MDD | completed, met | "On October 31, 2023, the Company announced Phase 2a interim results for CYB003, its proprietary deuterated psilocin molecule, demonstrating a rapid, robust and statistically significant reduction in symptoms of depression three weeks following a single 12mg dose compared to placebo, in participants with moderate to severe MDD." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1833141/000183314125000043/cybin-mdaxq2x26.htm)) |
| November 30, 2023 | [HLP003 topline data readout](https://sec-api.dev/pdufa/hlp003) | HELP |  | completed, met | "On November 30, 2023, the Company announced positive Phase 2a topline results for HLP003, showing rapid and robust improvements in symptoms of depression after single doses of HLP003, with an average 14.1 point difference in MADRS score reduction between HLP003 and placebo which was statistically significant at 3 weeks (p<0.0001)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1833141/000183314126000100/helus-mdaxq2x27.htm)) |
| November 30, 2023 | [CYB003 topline data readout](https://sec-api.dev/pdufa/cyb003) | HELP |  | completed, met | "On November 30, 2023, the Company announced positive Phase 2a topline results for CYB003, showing rapid and robust improvements in symptoms of depression after single doses of CYB003, with an average 14.1 point difference in MADRS score reduction between CYB003 and placebo which was statistically significant at 3 weeks (p<0.0001)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1833141/000183314125000043/cybin-mdaxq2x26.htm)) |
| January 8, 2024 | [HLP004 topline data readout](https://sec-api.dev/pdufa/hlp004) | HELP |  | completed, positive | "On January 8, 2024, the Company announced positive topline results from its Phase 1 studies of its proprietary molecules, HLP004 and SPL028." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1833141/000183314126000100/helus-mdaxq2x27.htm)) |
| January 8, 2024 | [CYB004 topline data readout](https://sec-api.dev/pdufa/cyb004) | HELP |  | completed, positive | "On January 8, 2024, the Company announced positive topline results from its Phase 1 studies of its proprietary deuterated DMT molecules, CYB004 and SPL028." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1833141/000183314125000043/cybin-mdaxq2x26.htm)) |
| March 15, 2024 | [HLP004 trial start](https://sec-api.dev/pdufa/hlp004) | HELP | moderate to severe GAD | completed | "On March 15, 2024, the Company announced that it had initiated a Phase 2 study of IM HLP004 in participants with moderate to severe GAD." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1833141/000183314126000100/helus-mdaxq2x27.htm)) |
| March 15, 2024 | [CYB004 trial start](https://sec-api.dev/pdufa/cyb004) | HELP | moderate to severe GAD | completed | "On March 15, 2024, the Company announced that it had initiated a Phase 2 study of IM CYB004 in participants with moderate to severe GAD." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1833141/000183314125000043/cybin-mdaxq2x26.htm)) |
| late 2024 | [Helus Pharma Inc. topline data readout](https://sec-api.dev/companies/help/catalysts) | HELP |  | scheduled | "The Company expects to spend approximately $5,720 to provide topline safety and efficacy data from Phase 2 GAD study around year end 2024 or early Q1 2025 of which approximately $2,205 was spent during the six months ended September 30, 2024 and approximately $58 was spent during the financial year ended March 31, 2024, resulting in an approximate remaining spend as of September 30, 2024 of $3,457 by Q4 2024.15" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1833141/000183314124000018/cybin-mdaxq2x25xseptember3.htm)) |
| Nov 2024 | [CYB003 trial start](https://sec-api.dev/pdufa/cyb003) | HELP | MDD in November 2024 | scheduled | "The Company anticipates to initiate a multinational Phase 3 study evaluating CYB003 in participants with MDD in November 2024.9" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1833141/000183314124000018/cybin-mdaxq2x25xseptember3.htm)) |
| Q1 2025 | [CYB004 topline data readout](https://sec-api.dev/pdufa/cyb004) | HELP |  | scheduled | "- Topline efficacy data from Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder ("GAD") expected in Q1 2025 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1833141/000162828025001391/a01-13x2025cybnyearxendprf.htm)) |
| Q1 2025 | [CYB003 topline data readout](https://sec-api.dev/pdufa/cyb003) | HELP | generalized anxiety disorder | scheduled | "Having aligned on trial design with the FDA, we recently initiated our Phase 3 PARADIGMTM pivotal program which will evaluate CYB003's efficacy and safety in a larger MDD population, and we expect to report Phase 2 topline results for CYB004, our proprietary deuterated dimethyltryptamine program for the treatment of generalized anxiety disorder, in the first quarter of 2025.1 We are committed to building on the positive clinical results to-date in both programs and to progressing CYB003 toward potential regulatory approval and commercialization," concluded Drysdale." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1833141/000106299324019233/exhibit99-1.htm)) |
| 1H 2025 | [Helus Pharma Inc. topline data readout](https://sec-api.dev/companies/help/catalysts) | HELP |  | scheduled | "The Company expects to spend approximately $10,014 to provide topline safety and efficacy data from Phase 2 GAD study in the first half of 2025 of which approximately $4,534 was spent during the nine months ended December 31, 2024 and approximately $58 was spent during the financial year ended March 31, 2024, resulting in an approximate remaining spend as of December 31, 2024 of $5,422 by the first half of 2025.19" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1833141/000183314125000001/cybin-mdaxq3x25xdecember31.htm)) |
| mid-2025 | [CYB003 trial start](https://sec-api.dev/pdufa/cyb003) | HELP |  | scheduled | "Forward-looking statements in this news release include statements regarding the Company's expectations respecting the patent exclusivity period; commencement of the second Phase 3 study, EMBRACE, in mid-2025; and the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1833141/000162828025023930/a05-08x2025cyb003patentprf.htm)) |
| Q1 2026 | [CYB004 topline data readout](https://sec-api.dev/pdufa/cyb004) | HELP | Generalized Anxiety Disorder | scheduled | "We are proud of this work to date, as well as the robust patent protection in support of our CYB004 program, and we look forward to sharing topline data in the first quarter of 2026."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1833141/000183314125000021/a09-2025cyb004enrollmentco.htm)) |
| Q1 2026 | [Helus Pharma Inc. topline data readout](https://sec-api.dev/companies/help/catalysts) | HELP |  | scheduled | "The Company expects to spend approximately $81017 to provide topline data readout from the Phase 2 GAD study by the milestone completion in Q1 2026 of which nil was spent during the nine months ended December 31, 2025, resulting in an approximate remaining spend of $810 by the milestone completion in Q1 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1833141/000183314126000012/cybin-mdaxq3x26.htm)) |
| Q1 2026 | [Helus Pharma Inc. topline data readout](https://sec-api.dev/companies/help/catalysts) | HELP |  | scheduled | "•Topline data expected first quarter of 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1833141/000183314125000025/cybncorpupdatesept232025pr.htm)) |
| Q1 2026 | [HLP004 topline data readout](https://sec-api.dev/pdufa/hlp004) | HELP | generalized anxiety disorder, with Phase 2 topline data readout | scheduled | "•Findings reinforce the therapeutic potential of short-acting serotonergic agonists and inform Helus Pharma's HLP004 development program, with Phase 2 topline data in generalized anxiety disorder ("GAD") expected in Q1 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1833141/000183314126000014/naturemedicinedmtpressrele.htm)) |
| 2026 | [CYB003 topline data readout](https://sec-api.dev/pdufa/cyb003) | HELP |  | scheduled | "oAPPROACH has been initiated and will enroll 220 participants at 36 clinical sites across the U.S. and Europe; topline results expected in 2026 oEMBRACE will enroll 330 participants at sites across the U.S. and Europe and is expected to commence by mid 2025 oEXTEND is expected to begin 12 weeks after commencement of APPROACH and EMBRACE, respectively" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1833141/000162828025001391/a01-13x2025cybnyearxendprf.htm)) |
| Q4 2026 | [HLP003 topline data readout](https://sec-api.dev/pdufa/hlp003) | HELP |  | scheduled | "The Company continues to anticipate reporting topline data from its Phase 3 APPROACH pivotal study of HLP003 in major depressive disorder in Q4 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1833141/000183314126000094/materialchangereport-leade.htm)) |
| Q4 2026 | [HLP004 topline data readout](https://sec-api.dev/pdufa/hlp004) | HELP |  | scheduled | "Mr. Cola's appointment comes at a pivotal moment as Helus advances its pipeline of next-generation mental health therapies toward key clinical and corporate value-inflection milestones, including the expected release of Phase 2 data for HLP004 this quarter and Phase 3 topline data for HLP003 in Q4 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1833141/000183314126000006/helusceopressreleasedraft-.htm)) |
| Q4 2026 | [HLP003 NDA/BLA submission](https://sec-api.dev/pdufa/hlp003) | HELP |  | scheduled | "The Company's near-term prospects and the market price of the Common Shares depend substantially on the success of HLP003, including the topline results of APPROACH expected in Q4 2026, the completion of EMBRACE and EXTEND, and the submission and acceptance of an NDA, regulatory approval and DEA rescheduling." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1833141/000183314126000100/helus-mdaxq2x27.htm)) |
| Q1 2027 | [HLP004 trial start](https://sec-api.dev/pdufa/hlp004) | HELP |  | scheduled | "The Company expects to spend approximately $6,329 to initiate a Phase 2 monotherapy study by the end of Q1 2027.16 No amounts were spent toward the achievement of this milestone during the six months ended September 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1833141/000183314126000100/helus-mdaxq2x27.htm)) |
| June 30, 2027 | [CYB003 topline data readout](https://sec-api.dev/pdufa/cyb003) | HELP |  | scheduled | "Each Warrant will be exercisable to acquire one Common Share at a price of US$8.14 per Common Share at any time prior to the earlier of: (i) June 30, 2027; (ii) thirty days following the publication by press release of topline data for the APPROACH trial of CYB003 in major depressive disorder; and (iii) thirty days following the date a press release is issued by the Company announcing exercise of its acceleration right, which right can only be exercised if the closing price of the Common Share on NYSE American LLC (the "NYSE American") is equal to or exceeds US$19.53 per Common Share for any five consecutive trading days." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1833141/000183314125000046/materialchangereportcybin-.htm)) |

## Drugs

- [CYB003](https://sec-api.dev/pdufa/cyb003): moderate to severe mdd, generalized anxiety disorder, mdd and other mental health conditions, mdd in november 2024
- [CYB004](https://sec-api.dev/pdufa/cyb004): moderate to severe gad, generalized anxiety disorder
- [HLP003](https://sec-api.dev/pdufa/hlp003): moderate to severe mdd
- [HLP004](https://sec-api.dev/pdufa/hlp004): moderate to severe gad, generalized anxiety disorder, with phase 2 topline data readout

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/help/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "HELP catalysts: Helus Pharma Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/help/catalysts

```bibtex
@misc{secapidev_companies_help_catalysts_20261116,
  title        = {HELP catalysts: Helus Pharma Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/help/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_help_catalysts_20261116","title":"HELP catalysts: Helus Pharma Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/help/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
